Q1 2024 EPS Estimates for BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Increased by Analyst

BioXcel Therapeutics, Inc. (NASDAQ:BTAI) – Analysts at HC Wainwright upped their Q1 2024 EPS estimates for BioXcel Therapeutics in a research report issued to clients and investors on Monday, April 15th. HC Wainwright analyst R. Selvaraju now anticipates that the company will post earnings per share of ($0.69) for the quarter, up from their prior forecast of ($0.93). HC Wainwright has a “Buy” rating and a $11.00 price objective on the stock. The consensus estimate for BioXcel Therapeutics’ current full-year earnings is ($2.46) per share. HC Wainwright also issued estimates for BioXcel Therapeutics’ Q2 2024 earnings at ($0.63) EPS, Q3 2024 earnings at ($0.59) EPS, Q4 2024 earnings at ($0.54) EPS and FY2024 earnings at ($2.42) EPS.

Other equities analysts have also issued reports about the company. Bank of America decreased their price target on BioXcel Therapeutics from $8.00 to $7.00 and set a “buy” rating on the stock in a research note on Wednesday, March 13th. Canaccord Genuity Group lowered their price target on shares of BioXcel Therapeutics from $18.00 to $7.00 and set a “buy” rating for the company in a report on Thursday, March 14th. Finally, UBS Group reissued a “neutral” rating and set a $4.00 price target (down previously from $9.00) on shares of BioXcel Therapeutics in a research report on Wednesday, February 21st. Four analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. Based on data from MarketBeat, BioXcel Therapeutics presently has a consensus rating of “Hold” and an average price target of $16.86.

BioXcel Therapeutics Trading Up 7.8 %

BTAI opened at $2.75 on Thursday. BioXcel Therapeutics has a 12 month low of $1.91 and a 12 month high of $29.56. The business’s 50-day moving average price is $2.90 and its 200-day moving average price is $3.18. The company has a market cap of $84.10 million, a P/E ratio of -0.45 and a beta of 0.40.

BioXcel Therapeutics (NASDAQ:BTAI) last posted its quarterly earnings results on Tuesday, March 12th. The company reported ($0.76) earnings per share for the quarter, topping the consensus estimate of ($0.98) by $0.22. BioXcel Therapeutics had a negative net margin of 12,974.86% and a negative return on equity of 890.63%. The business had revenue of $0.38 million during the quarter, compared to the consensus estimate of $1.17 million.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the stock. Virtu Financial LLC purchased a new position in shares of BioXcel Therapeutics during the fourth quarter valued at about $176,000. Barclays PLC boosted its position in BioXcel Therapeutics by 264.4% during the 4th quarter. Barclays PLC now owns 27,895 shares of the company’s stock valued at $82,000 after acquiring an additional 20,239 shares in the last quarter. Pennant Investors LP bought a new stake in BioXcel Therapeutics during the 4th quarter valued at approximately $248,000. Tower Research Capital LLC TRC grew its holdings in shares of BioXcel Therapeutics by 239.2% during the 4th quarter. Tower Research Capital LLC TRC now owns 13,832 shares of the company’s stock worth $41,000 after acquiring an additional 9,754 shares during the period. Finally, Cambridge Investment Research Advisors Inc. bought a new position in shares of BioXcel Therapeutics in the 4th quarter worth approximately $112,000. 30.68% of the stock is currently owned by institutional investors.

About BioXcel Therapeutics

BioXcel Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices.